The Central Marine Fisheries Research Institute (CMFRI) has commercialised the patent-protected technologies of two seaweed-based nutraceutical products — one to boost anti-viral immunity and the other to combat high cholesterol or dyslipidemia. The products are expected to reach the market within six months from Pioneer Pharmaceuticals.
A communication from ICAR-CMFRI said A. Gopalakrishnan, Director of the institute, had signed a licence agreement with Joby George, managing partner, Pioneer Pharmaceuticals Limited, a wellness and pharmaceutical company based in Kochi, for commercial production and marketing of the products.
The nutraceuticals are a 100% natural blend of highly nutritious bioactive ingredients extracted with eco-friendly ‘green’ technology, Dr. Gopalakrishnan said.
The nutraceutical products contain 100% natural marine bioactive ingredients from selected seaweeds, which are commonly available in the Indian coastal waters, a CMFRI release said. The Institute has successfully brought out nutraceuticals targeting a range of lifestyle diseases such as type-2 diabetes, arthritis, hypertension, hypothyroidism, osteoporosis, and fatty liver.
